Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene + decitabine in relapsed/refractory pediatric solid tumors (DACTBT PI/II)
jRCT2091220376Phase 2Completed
- Sponsor
- Junichi Hara
- Start
- Aug 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamibarotene and decitabine in neuroblastoma, Bone and soft tissue sarcoma, blastoma and 3 more, sponsored by Junichi Hara. Primary endpoints: Event rate of dose-limiting toxicity and Progression-free survival. Started Aug 2018; status: completed.
02
Drugs
tamibarotenedecitabine
03
Conditions
neuroblastomaBone and soft tissue sarcomablastomagerm cell tumor (GCT)central nervous system tumor
Beyond the preview
Go deeper on jRCT2091220376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220376.